Hemostemix Inc. announced a non-brokered private placement of up to 15,000,000 units on May 19, 2022. Each unit consists of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional share at a price of CAD 0.55 per share for a period of 24 months from the date the units are issued.

If during any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the offering, the average closing sales price of the common shares as quoted on the TSX Venture Exchange is greater than or equal to CAD 0.55 per common share, the company may provide notice in writing to the holders of the warrants by issuance of a press release that the expiry date of the warrants will be accelerated to the 30th day after the date on which the company issues such press release. The company may pay finders' fees of 8 per cent that are payable in connection with the closing. The transaction is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange.

All securities issued in connection with the transaction will be subject to a four-month hold period from the closing date.